These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1636 related articles for article (PubMed ID: 17126425)

  • 1. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
    Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
    Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
    Abrams SL; Steelman LS; Shelton JG; Wong EW; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 May; 9(9):1781-91. PubMed ID: 20436278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
    Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines.
    Chappell WH; Candido S; Abrams SL; Akula SM; Steelman LS; Martelli AM; Ratti S; Cocco L; Cervello M; Montalto G; Nicoletti F; Libra M; McCubrey JA
    Aging (Albany NY); 2020 Jun; 12(11):10194-10210. PubMed ID: 32492656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
    Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA
    Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
    McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
    Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.
    Zhang X; Liu G; Ding L; Jiang T; Shao S; Gao Y; Lu Y
    J Cell Biochem; 2018 Mar; 119(3):2864-2874. PubMed ID: 29073728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
    Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
    Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
    Park JI; Strock CJ; Ball DW; Nelkin BD
    Mol Cell Biol; 2003 Jan; 23(2):543-54. PubMed ID: 12509453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Franklin RA; Montalto G; Cervello M; Libra M; Candido S; Malaponte G; Mazzarino MC; Fagone P; Nicoletti F; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Chiarini F; Evangelisti C; Cocco L; Martelli AM
    Oncotarget; 2012 Oct; 3(10):1068-111. PubMed ID: 23085539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.